Nicolas Charhon

Learn More
INTRODUCTION Diagnosis of peritoneal tuberculosis (pTB) is difficult, even in developed countries, where data are lacking. The aim of the present study was to describe the clinical presentation, diagnosis, and bacterial epidemiology of pTB in France over a 10-year period. METHODS A retrospective study was conducted on pTB in two university hospitals in(More)
Most aminoglycoside pharmacokinetic models include an index of renal function, such as creatinine clearance, to describe drug clearance. However, the best clinical descriptor of renal function for the pharmacokinetic modeling of aminoglycosides has not been established. This analysis was based on 412 gentamicin concentrations from 92 geriatric patients who(More)
BACKGROUND Recent literature reports of potential adverse effects (AEs) of proton pump inhibitors (PPIs), especially during long-term treatments. PURPOSE To present a literature review of major AEs: digestive infections, pneumonia, bone fracture, hypomagnesemia, interstitial nephritis, gastric cancer and neutropenia. DATA SOURCES The authors used(More)
PURPOSE In France, efforts to optimize prescribing of proton-pump inhibitors (PPIs) are rare. Various studies have shown that the prescription of these drugs is excessive. This has consequences regarding costs and iatrogenesis. The objective of this study was to describe the type of drug related problems (DRP) and pharmaceutical interventions reported by(More)
A 64-year-old Caucasian male was admitted to the infectious disease department in May 2016 for exploration of a febrile syndrome lasting for two months associated with chronic cough for 1 year. He was treated by Everolimus (Certican®) 1 mg bid since 2011 as anti-rejection drug after cardiac transplantation in 1990. His treatment also included Atorvastatin(More)
INTRODUCTION Several case reports have reported the benefit of intravenous immunoglobulin therapy in many autoimmune diseases, including systemic lupus erythematosus. CASE REPORTS Here, we report on two cases of lupus myocarditis treated with high dose of intravenous immunoglobulin. The first patient was a 42-year-old woman who presented with lupus(More)
Previously published papers indicate that the adverse effects (AEs) of intravenous immunoglobulin (IVIG) were observed in up to 30% of treated patients [1]. Patients treated by IVIG are more likely to experience certain AEs at higher infusion rates [2]. We report a case of circulatory collapse induced by off-label IVIG treatment used for modulation of(More)
  • 1